TABLE I.
Characteristics of the 643 Patients and Overall Survival Rates by Prognostic Variables
| Variables | No | 5-year OS (%) | 10-year OS (%) | RR of death | Log-rank test (P) |
|---|---|---|---|---|---|
| Total | 643 | 67 | 62 | ||
| Sex | |||||
| Male | 327 | 66 | 62 | 1.1 | NS |
| Female | 316 | 69 | 62 | 1 | |
| Age | |||||
| <3 | 189 | 79 | 71 | 1 | |
| 3–9 | 232 | 65 | 61 | 1.6 | 0.03 |
| 10+ | 222 | 59 | 54 | 1.9 | |
| Age | |||||
| <3 | 189 | 79 | 71 | 1 | <0.001 |
| 3+ | 454 | 62 | 58 | 1.7 | |
| Site of primary | |||||
| Upper limb | 264 | 66 | 61 | ||
| Lower limb | 373 | 68 | 62 | NS | |
| Site of primary | |||||
| Hand and foot | 108 | 57 | 55 | 1.3 | |
| Other | 529 | 69 | 63 | 1 | 0.08 |
| T status | |||||
| T1 | 398 | 75 | 70 | 1 | |
| T2 | 222 | 54 | 49 | 2.1 | <0.001 |
| Unknown | 23 | ||||
| Tumor size | |||||
| <5 cm | 270 | 75 | 70 | 1 | |
| >5 cm | 364 | 62 | 56 | 1.7 | 0.002 |
| Unknown | 9 | ||||
| Clinical stage | |||||
| I | 346 | 78 | 71 | 1 | |
| II | 133 | 58 | 53 | 2.1 | <0.001 |
| III | 131 | 51 | 46 | 2.5 | |
| Unknown | 33 | ||||
| Regional node involvement | |||||
| No | 495 | 72 | 66 | 1 | <0.001 |
| Yes | 131 | 51 | 46 | 1.9 | |
| Unknown | 17 | ||||
| Pathology | |||||
| Non alveolar | 223 | 72 | 68 | 1 | 0.06 |
| Alveolar | 420 | 65 | 58 | 1.4 | |
| Initial surgery | |||||
| Complete | 148 | 82 | 77 | 1 | |
| Micro residue | 153 | 71 | 66 | 1.6 | <0.001 |
| Macro residue or biopsy | 101+239 | 59 | 52 | 2.8 | |
| Chemotherapy | |||||
| VA | 39 | 84 | 81 | 1 | |
| Alkyating agents (AA) | 307 | 69 | 64 | 2 | 0.04 |
| AA + any anthracyclines | 197 | 64 | 57 | 2.4 | |
| 6 drugs (CEVAIA) | 94 | 57 | 55 | 2.7 | |
| Unknown | 6 | ||||
| Initial radiation | |||||
| No | 231 | 68 | 64 | 1 | |
| Yes | 388 | 66 | 59 | 1.1 | NS |
| Unknown or amputation | 24 | ||||
| Cooperative groups | |||||
| COG | 300 | 72 | 68 | 1 | |
| CWS | 139 | 63 | 54 | 1.5 | 0.02 |
| ICG | 44 | 64 | 59 | 1.5 | |
| SIOP | 160 | 61 | 56 | 1.5 | |
| Cooperative groups | |||||
| COG | 300 | 72 | 68 | 1 | 0.002 |
| Europe | 343 | 62 | 56 | 1.5 | |
| Era of treatment | |||||
| 1984–1994 | 355 | 62 | 57 | 1.5 | 0.004 |
| 1995+ | 288 | 73 | 68 | 1 |
NS, not statistically significant.